MarketPeel
Insider Trading Intelligence
AS

Adam Savitz

ANRO
CHIEF MEDICAL OFFICER · ALTO NEUROSCIENCE, INC. · CIK 0002008707
FILING MIX · LIFETIME68%/32%
BUYS
13
SELLS
6
TOTAL VALUE
$462.8K
COMPANIES
1
ACTIVE SINCE
Feb 2024
HOLDINGS NOW
124,000
AVG SELL PX
TRADE KIND
SHOWING 19 / 19
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Adam Savitz, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+75.00%+9.68%+0.62%+9.06%+16.25%
14d4+75.00%+4.31%-0.94%+5.25%+15.35%
30d4+0.00%-30.36%-2.47%-27.89%-27.30%
60d4+75.00%-3.16%-0.74%-2.43%+2.93%
90d4+0.00%-17.23%+3.06%-20.29%-18.51%
180d4+0.00%-63.18%+6.94%-70.12%-73.52%
1y4+0.00%-79.65%+15.78%-95.43%-93.72%
2y4(3 pending)+0.00%-27.23%+39.35%-66.58%-66.58%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ANRO · 124,000 shares · as of Feb 11, 2026
031,00062,00093,000124,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 13 buys / 6 sellsCOVERAGE · 9 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
124,000124,000Feb 11, 2026Feb 13, 2026View →
ANRO
ALTO NEUROSCIENCE, INC.
SALE
CHIEF MEDICAL OFFICER
76,0000Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
SALE
CHIEF MEDICAL OFFICER
22,4810Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
76,00076,000Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
73,00073,000Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
22,48122,481Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
123,645123,645Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
SALE
CHIEF MEDICAL OFFICER
123,6450Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
SALE
CHIEF MEDICAL OFFICER
33,0080Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
SALE
CHIEF MEDICAL OFFICER
73,0000Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
33,00833,008Jul 3, 2025Jul 8, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
76,00076,000Feb 5, 2025Feb 7, 2025View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASE
CHIEF MEDICAL OFFICER
2,931$13.22$38.7K39,851Jul 10, 2024Jul 11, 2024View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASE
CHIEF MEDICAL OFFICER
1,388$13.15$18.3K36,920Jul 9, 2024Jul 11, 2024View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASE
CHIEF MEDICAL OFFICER
10,681$12.53$133.8K35,532Jul 9, 2024Jul 11, 2024View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASEGRANT
Stock grant
73,00073,000Mar 1, 2024Mar 5, 2024View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASE
CHIEF MEDICAL OFFICER
17,000$16.00$272.0K24,851Feb 6, 2024Feb 7, 2024View →
ANRO
ALTO NEUROSCIENCE, INC.
SALE
CHIEF MEDICAL OFFICER
16,6660Feb 6, 2024Feb 7, 2024View →
ANRO
ALTO NEUROSCIENCE, INC.
PURCHASE
CHIEF MEDICAL OFFICER
7,8517,851Feb 6, 2024Feb 7, 2024View →
Other insiders · ANRO
Loading peer insiders…
About this filer
CIK 0002008707
ROLE
CHIEF MEDICAL OFFICER
PRIMARY
ANRO
COMPANIES
1
ACTIVE SINCE
Feb 2024
MARKETPEEL · /INSIDER/0002008707DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback